BHP Attracts AI-Focused Investors as Copper Demand Surges 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
PHILADELPHIA, May 01, 2018 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, May 8, 2018, at 8:30 a.m. ET to discuss corporate and financial results for the first quarter that ended March 31, 2018, and recent business highlights.
The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 1483429. To access a live audio webcast, please visit the “Investors” section at www.sparktx.com.
A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 1483429, or by visiting the “Investors” section at www.sparktx.com.
About Spark Therapeutics
At Spark Therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. We have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.
| Investor Contact: Ryan Asay [email protected] (215) 239-6424 | Media Contact: Monique da Silva [email protected] (215) 282-7470 |
